Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Veeva Systems Inc.
VEEV
NYSE·Healthcare·Medical - Healthcare Information Services·Mkt cap $29.9B
$192.74
▲ +4.62%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$148.05 - $310.50
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 34.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Industry-specific expertise and deep domain knowledge in life sciences regulatory and commercial operations
- Integrated platform ecosystem reducing customer switching costs and increasing customer lifetime value
- Proprietary data assets and analytics capabilities through Veeva Data Cloud and Crossix
- Strong customer relationships with major pharmaceutical and biotech companies creating high retention rates
- Cloud-native architecture enabling rapid innovation and scalability across global markets
Bear Case
1 risk
- Average volatility.
Growth
Moderate growth ahead
Digital transformation acceleration in life sciences driving cloud adoption and software spending
Value
Fairly valued vs Enterprise SaaS peers
Momentum
Strong
+5.9% over 3m
Quality
Excellent
Excellent business quality
Dividend
None
No dividend
Smart-money signal
Who's buying VEEV right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Aug 26, 2026
JUN 3, 2026
Reported EPS of $2.24 vs $2.14 consensus (+4.7% surprise). Revenue of $882.9M vs $857.7M expected (+2.9%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+4.7%
Next: Aug 26, 2026
Revenue trend · last 8Q
—
—
—
+14%
+17%
+17%
+16%
+16%
Q1 24
Q2 24
Q3 24
Q4 25
Q1 25
Q2 25
Q3 25
Q4 26
$650.3M
$676.2M
$699.2M
$720.9M
$759.0M
$789.1M
$811.2M
$836.0M
Margins · last 8Q
Gross
74.5%
Operating
29.4%
Profit
29.2%
Wall Street consensus
18 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
28%
Sell
6%
Median Price Target
—
Latest: Wells Fargo · Jun 4, 2026